Phase 3 results for Sun Pharma’s investigational psoriasis medicine, tildrakizumab

Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with...

Read More